QA-GSH, a quaternary ammonium glutathione analogue conjugating agent, can provide semiquantitative assessment of bioactivation potential for semiquantitative LC-MS/MS detection of reactive metabolite
Bioactivation of drug candidates resulting in chemically reactive, electrophilic metabolites have always presented a major challenge to pharmaceutical companies.
Moreover, the measurement of these metabolites has been hampered by the lack of an effective quantitative method.
QA-GSH is a novel new tool for the detection of reactive metabolites.
QA-GSH is a novel quaternary ammonium glutathione analogue conjugating agent described by Soglia, et al.
Developed by Pfizer, this compound can provide semiquantitative assessment of the bioactivation potential in vitro for semiquantitative LC-MS/MS detection of reactive metabolite.
The methodology is well suited for use in early drug discovery high throughput screening paradigms.
QA-GSH is available from AnaSpec, a provider of integrated proteomics.
